Table 5 Adverse events (AEs) reported during the treatment phase and tapering off phase by >5% of participants
Preferred term | Total AEs n (%) |
|---|---|
Treatment phase (N = 104) | |
Nausea | 51 (32%) |
Vomiting | 41 (26%) |
Somnolence | 25 (16%) |
Dizziness | 14 (9%) |
Constipation | 10 (6%) |
Asthenia | 9 (6%) |
Pruritus | 8 (5%) |
Tapering off phase (N = 42) | |
Nausea | 5 (10%) |
Vomiting | 3 (6%) |